EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID60955906

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID60955906


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	NSKVIUBXDJHCAL-UHFFFAOYSA-N
Smiles	O=P(OC=1C=CC=CC1)(OC=2C=CC=CC2)OC=3C=CC=CC3C(C=4C=CC=CC4)(C)C
InChI	InChI=1/C27H25O4P/c1-27(2,22-14-6-3-7-15-22)25-20-12-13-21-26(25)31-32(28,29-23-16-8-4-9-17-23)30-24-18-10-5-11-19-24/h3-21H,1-2H3

InChI Key

NSKVIUBXDJHCAL-UHFFFAOYSA-N

Smiles

O=P(OC=1C=CC=CC1)(OC=2C=CC=CC2)OC=3C=CC=CC3C(C=4C=CC=CC4)(C)C

InChI

InChI=1/C27H25O4P/c1-27(2,22-14-6-3-7-15-22)25-20-12-13-21-26(25)31-32(28,29-23-16-8-4-9-17-23)30-24-18-10-5-11-19-24/h3-21H,1-2H3

Property Name	Value
Molecular Formula	C27H25O4P
Molecular Weight	444.15
AlogP	7.66
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	44.76
Molecular species	None
Aromatic Rings	4.0
Heavy Atoms	32.0

Property Name

Value

Molecular Formula

C27H25O4P

Molecular Weight

444.15

AlogP

7.66

Hydrogen Bond Acceptor

4.0

Hydrogen Bond Donor

0.0

Number of Rotational Bond

8.0

Polar Surface Area

44.76

Molecular species

None

Aromatic Rings

4.0

Heavy Atoms

32.0

Resources	Reference
CAS NUMBER	34364-42-6
NORMAN SUSDAT
PubChem	20295726

Resources

Reference

CAS NUMBER

34364-42-6

NORMAN SUSDAT

PubChem

20295726


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

(1-METHYL-1-PHENYLETHYL)PHENYL DIPHENYL PHOSPHATE

Structure

Physicochemical Descriptors

Cross References